Table 2.

Zeranol metabolite concentrations measured using a validated method on the Thermo Q Exactive HF Hybrid Quadrupole-Orbi MS collected from a cohort of pregnant NJ women. Zeranol concentrations have been corrected for urinary dilution by specific gravity as described by Bandera et al. [9]*. For measurements below the reported LOD, %CV has been recorded as an expression of uncertainty

	Zeranol concentration in urine (ng/mL)
Sample ID	bZal	bZol	Zer	aZol	Zan	Zen	∑mycoestrogen
1	nd	0.0454	0.0062	0.0968	nd	0.156	0.304
2	nd	0.0221	nd	0.149	nd	0.0871	0.258
3	nd	0.123	nd	0.511	nd	0.559	1.19
4	nd	0.0268	nd	0.0574	nd	0.0832 (28%)	0.167
5	nd	0.0247	nd	0.166	nd	0.179	0.369
6	nd	0.232	nd	0.948	0.0215 (7.5%)	2.85	4.05
7	nd	0.0136 (48%)	nd	0.122	0.0051 (26%)	0.185	0.326
8	nd	0.0379	nd	0.0785	0.0020 (9.3%)	0.139	0.258
9	nd	0.0582	nd	0.0417 (1.6%)	0.0038 (6.6%)	0.0760 (9.9%)	0.180
10	nd	0.0222	nd	0.0588	0.0017 (33%)	0.112	0.194

Bolded values (%) = values approximated below the reported LOD using integrated peak area (%CV)

nd non-detect; no analyte signal was detected at the retention time

∑_mycoestrogen = sum of all zeranol metabolites

^*Mycoestrogen_{SG corrected} = mycoestrogen value/[(SG − 1) × 100]